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Abstract  
 
4-Methylmethcathinone (2-methylamino-1-(4-methylphenyl)propan-1-one, 
mephedrone) is a psychoactive substance that has been associated with 
recreational use worldwide. Analytical data related to mephedrone are 
abundantly available but the characterization of by-products obtained 
during organic synthesis remains to be explored. This study presents the 
identification of a 1,2,3,5-tetramethyl-4-(4- methylphenyl)-1H-imidazol-3-
ium salt (TMMPI), which was formed during the synthesis of mephedrone. 
When diethyl ether was added to the crude reaction product, solid material 
precipitated from the solution. Analytical characterization of TMMPI 
employed a range of analytical techniques including chromatographic 
analysis in combination with various mass spectrometric detection 
methods, nuclear magnetic resonance spectroscopy and crystal structure 
analysis. Additional confirmation was obtained from organic synthesis of 
the imidazolium by-product. When TMMPI was subjected to analysis by gas 
chromatography-mass spectrometry (GC-MS), isomerization and 
degradation into two distinct compounds were observed, which pointed 
toward thermal instability under GC conditions. An LC-MS based 
investigation into a micro scale synthesis of mephedrone and three 
additional analogues revealed that the corresponding TMMPI analogue was 
formed. Interestingly, storage of mephedrone freebase in a number of 
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organic solvents also gave rise to TMMPI and it appeared that its formation 
during storage was significantly reduced in the absence of air. The present 
study was aimed to support clandestine forensic investigations by 
employing analytical strategies that are applicable to manufacturing sites. 
The imidazolium salts will most likely be found amongst the waste products 
of any clandestine lab site under investigation rather than with the desired 
product.  
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Abstract 
4-Methylmethcathinone (2-methylamino-1-(4-methylphenyl)propan-1-one, 
mephedrone) is a psychoactive substance that has been associated with recreational 
use worldwide. Analytical data related to mephedrone are abundantly available but 
the characterization of by-products obtained during organic synthesis remains to be 
explored. This study presents the identification of a 1,2,3,5-tetramethyl-4-(4-
methylphenyl)-1H-imidazol-3-ium salt (TMMPI), which was formed during the 
synthesis of mephedrone. When diethyl ether was added to the crude reaction 
product, solid material precipitated from the solution. Analytical characterization of 
TMMPI employed a range of analytical techniques including chromatographic 
analysis in combination with various mass spectrometric detection methods, nuclear 
magnetic resonance spectroscopy and crystal structure analysis. Additional 
confirmation was obtained from organic synthesis of the imidazolium by-product. 
When TMMPI was subjected to analysis by gas chromatography-mass spectrometry 
(GC-MS), isomerization and degradation into two distinct compounds were 
observed, which pointed toward thermal instability under GC conditions. An LC-MS 
based investigation into a micro scale synthesis of mephedrone and three additional 
analogues revealed that the corresponding TMMPI analogue was formed. 
Interestingly, storage of mephedrone freebase in a number of organic solvents also 
gave rise to TMMPI and it appeared that its formation during storage was 
significantly reduced in the absence of air. The present study was aimed to support 
clandestine forensic investigations by employing analytical strategies that are 
applicable to manufacturing sites. The imidazolium salts will most likely be found 
amongst the waste products of any clandestine lab site under investigation rather 
than with the desired product.  
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Keywords: forensic; mephedrone; cathinones; synthesis; imidazolium, by-product; 
TMMPI.  
 
Introduction 
The cathinone molecular scaffold gives rise to a large range of biologically active 
compounds and a considerable number of substituted cathinones has gained 
popularity amongst drug users. These substances were often accessible to the general 
public, for example, via specialized street shops (e.g. head shops/smart shops), and 
the Internet that included retailers operating in the ‘surface’ net or hidden ‘dark’ net 
environment. The rapid emergence of these largely un-tested new psychoactive 
substances (NPS) has raised concerns worldwide from emergency personnel, 
clinicians, policy makers, law enforcement and the general public.[1,2, 3] Amongst the 
more frequently encountered substituted cathinones, which showed some form of 
diffusion into specific subpopulations was 4-methylmethcathinone (mephedrone). 
When mephedrone was controlled under the Irish misuse of drugs legislation, it was 
encountered on the Irish illicit market where it was typically sold either as a powder 
purporting to be cocaine or in a tablet form purporting to represent 3,4-
methylenedioxymethamphetamine (MDMA). [4,5]  
 
The synthesis of mephedrone was first published in 1929 by Saem de Burnaga 
Sanchez.[6] The route involved the bromination of 4-methylpropiophenone to yield 4-
methyl-2-bromopropiophenone which, when reacted with methylamine hydrochloride 
and triethylamine as an acidic scavenger, gave mephedrone. The reaction was 
quenched with hydrogen chloride (aqueous or gaseous) that provided the racemic 
hydrochloride mephedrone salt. A Friedel-Crafts acylation route, starting with toluene 
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and propanoyl chloride in the presence of a suitable Lewis acid as a catalyst, may also 
be used to produce the 4-methylpropiophenone intermediate.[7] Another potential 
route to mephedrone synthesis involves the oxidation of 4-methylephedrine in a 
simple one step reaction process or a Grignard reaction using 4-methylbenzaldehyde 
as the starting material.[8]   
 
Detailed published information on possible synthetic mephedrone impurities and 
route-specific by-products are currently unavailable although it has been recognized 
that the formation of iso-cathinones may be relevant for the chemistry of synthetic 
cathinones.[9-11] Mephedrone pyrolysis has also been reported to yield a range of 
degradation products.[12] In addition, GC-based heat-induced formation of artifacts or 
decomposition products may be observed during the analysis of substituted 
cathinones, which deserves further study.[13-18]    
 
As part of the authors’ ongoing collective research efforts regarding the systematic 
preparation and forensically relevant characterization of targeted NPS, the present 
study reports on the formation of a by-product during m phedrone synthesis. During a 
series of experiments involving the use of a 33% methylamine solution and a number 
of different solvents containing  the α-bromo-4-methylpropiophenone, one 
experiment included the addition of diethyl ether to the crude mephedrone product (in 
preparation for forming a mephedrone hydrochloride salt). A solid product, however, 
was observed to precipitate from the solution, initally, this solid was presumed to be 
mephedrone freebase and accordingly filtered, dried and stored in a freezer for further 
work.  
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This product was subsequently identified as a 1,2,3,5-tetramethyl-4-(4-
methylphenyl)-1H-imidazol-3-ium salt (TMMPI). Analytical characterization 
included chromatographic techniques coupled with various forms of mass 
spectrometry, nuclear magnetic resonance spectroscopy, crystal structure analysis and 
additional confirmation by synthesis of this imidazolium by-product. The presence of 
TMMPI was also observed in the crude reaction mixtures of subsequent syntheses 
along with mephedrone and a mephedrone dimer. Given the polar salt nature of 
TMMPI, the data presented is also aimed to inform forensic investigators and 
researchers involved in the examination of waste products derived from clandestine 
manufacturing facilities suspected of synthesizing substituted cathinones. 
 
 
 
 
Experimental 
Reagents and standards 
All reagents and dry solvents used in the syntheses were obtained from Sigma Aldrich 
Ltd. (Arklow, Ireland). LC-MS grade solvents were obtained from Fisher Scientific 
(Dublin, Ireland). 
Isolation of the imidazolium by-product from a mephedrone reaction mixture. 
 
A solution of α-bromo-4-methylpropiophenone (5.68 g, 25 mmol) and ethanolic 
methylamine (6.25 mL, 8 M, 50 mmol) in absolute ethanol (50 mL) was stirred 
overnight at room temperature. The mixture was evaporated to a small volume under 
vacuum at room temperature and diethyl ether (150 mL) was added. After vigorous 
mixing, the mixture was filtered. The residue was extracted with acetonitrile (30 mL) 
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and filtered. The filtrate was evaporated to a small volume to afford a precipitate. The 
remaining solvent was removed with a pipette and the solid was washed with 
acetonitrile (3 x 1 mL). The residue was dissolved in dichloromethane (15 mL), 
filtered and the filtrate was evaporated to dryness under vacuum to give a colorless 
solid (172 mg). A sample was recrystallized (slow evaporation) from dichloromethane 
to afford colorless crystals (m. pt. 224 - 226 oC uncorrected ): 1H NMR (DMSO) δ 
7.42 (d, J=7.5 Hz, 2H, CH Ar),  7.42 (d, J=7.5 Hz, 2H, CH Ar),  3.74 (s, 3H, CH3),  
3.74 (s, 3H, CH3),  2.68 (s, 3H, CH3),  2.42 (s, 3H, CH3), 2.22 (s, 3H, CH3) ; 
 13C NMR (d6 DMSO) δ 144.2 (C imidazolium), 140.1 (C phenyl), 130.7 (C phenyl), 
129.5 (C imidazolium), 129.3 (C phenyl), 123.4 (C phenyl), 33.2 (C imidazolium), 
32.6 (C imidazolium), 21.4 (C phenyl methyl), 10.5 (C imidazolium), 9.2 (C 
imidazolium. HR-ESIMS found 215.1548 (theory M+: C14H19N2, 215.1548) 
 
 
1,2,3,5-Tetramethyl-4-(4-methylphenyl)-1H-imidazol-3-ium iodide synthesis 
 
A mixture of α-bromo-4-methylpropiophenone (1.22 g, 5.4 mmol), acetamidine 
hydrochloride (1.04 g, 10.9 mmol) and anhydrous potassium carbonate (2.20 g) in 
acetonitrile (120 mL) was refluxed for 15 hr. The mixture was cooled, filtered and 
evaporated to dryness to afford a light yellow powder (729 mg), which was dissolved 
in DMF (3 mL). A suspension of sodium hydride (115 mg, 4.8 mmol) in DMF (3 mL) 
was added and the mixture was stirred at room temperature for 2 h. Iodomethane (2 
mL) was added and the mixture was stirred for 3 h at room temperature. More 
iodomethane (2 mL) was added and the mixture was stirred overnight at room 
temperature. The mixture was diluted with acetonitrile (100 mL), filtered and the 
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volatiles were removed under vacuum. The residue was dissolved in diethyl ether 
(100 mL) and the precipitated solid was collected by filtration. The solid was mixed 
with dichloromethane (20 mL), filtered and the filtrate was concentrated to give a 
light yellow solid (234 mg). This was recrystallized from dichloromethane/tert-butyl 
methyl ether to afford a colorless solid (92 mg, m.p. 220 - 222 oC uncorrected ): 1H 
NMR (DMSO) δ 7.40 (d, J=7.5 Hz, 2H, CH Ar),  7.34 (d, J=7.5 Hz, 2H, CH Ar),  
3.73 (s, 3H, CH3),  3.56 (s, 3H, CH3),  2.68 (s, 3H, CH3),  2.40 (s, 3H, CH3), 2.21 (s, 
3H, CH3) ; 13C NMR (d6 DMSO) δ 143.6 (C imidazolium), 139.5 (C phenyl), 130.2 
(C phenyl), 129.7 (C imidazolium), 129.0 (C phenyl), 126.6 (C phenyl), 33.7 (C 
imidazolium), 31.9 (C imidazolium), 20.9 (C phenyl methyl), 10.1 (C imidazolium), 
9.7 (C imidazolium. HR-ESIMS found 215.1548 (theory M+: C14H19N2, 215.1543) 
 
 
Micro scale reactions for LC-MS analysis 
A solution of the α-bromo ketone (0.25 mmol) and the amine (0.5 mmol) in the 
specified solvent (500 µL) was allowed to stand at room temperature overnight. This 
solution was diluted with acetonitrile/water (1/1, containing 0.1 % formic acid, 1.5 
mL), an aliquot (8 µL) was further diluted with acetonitrile/water (1/1, containing 
0.1 % formic acid, 1 mL) and analyzed by LC-MS. 
 
Micro scale formation of TMMPI from freebase mephedrone 
A solution of freebase mephedrone in acetonitrile (0.5 mmol/500 µL acetonitrile, 100 
µL) and acetonitrile (100 µL) was allowed to stand overnight (in the presence or 
absence of air) at room temperature. This solution was diluted with acetonitrile/water 
(1/1, containing 0.1 % formic acid, 600 µL), an aliquot (8 µL) was further diluted 
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with acetonitrile/water (1/1, containing 0.1 % formic acid, 1 mL) and analyzed by 
LC-MS. The by-product formation was observed in the presence of air, but very 
significantly, this was observed to drop by over 90 % in the absence of air. 
 
Preparative formation of TMPPI from mephedrone freebase. 
 A solution of mephedrone free base (prepared from 2.15 g of the HCl salt, 10 mmol) 
was dissolved in acetonitrile and stirred at room temperature for 48 h. The solution 
was evaporated to dryness and the residual brown oil was washed with diethyl ether 
(4 x 10 mL). The residue was dissolved in dichloromethane and hydrogen chloride in 
2-propanol (5-6 M) was added. The mixture was concentrated to a small volume 
under vacuum, the supernatant was removed and drying was continued under vacuum 
to afford a light brown solid (219 mg). The supernatant was concentrated to give a 
brown oil (178 mg) which was analyzed by NMR and also used for further 
chromatographic analysis. 
 
Preparation of crude mephedrone hydrochloride. 
 
A solution of α-bromo-4-methylpropiophenone (1.13 g, 5 mmol) and ethanolic 
methylamine (1.25 mL, 8 M, 10 mmol) in absolute ethanol (10 mL) was stirred 
overnight at room temperature. The mixture was evaporated to dryness and, taken up 
in dichloromethane and a solution of hydrogen chloride in diethyl ether (2 M) was 
added. Removal of the volatiles afforded a brown powder (1.41 g) 
 
Instrumental analysis 
Gas chromatography - mass spectrometry  
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Samples were analyzed on an Agilent 6890N gas chromatograph coupled to a 5973 
MSD. A HP-5MS column (30 m × 0.25 mm × 0.25 µm) was used in splitless mode 
with helium carrier gas at a constant flow of 1 mL/min. The injection port and transfer 
line temperatures were set at 250 °C and 280 °C, respectively. The initial oven 
temperature was 90 °C, held for 1 min, then ramped at 15 °C/min to 280 °C and held 
for 5 min, followed by a ramp of 20 °C/min to 300 °C with a final hold time of 1 min. 
The mass spectra data was collected after a 5 minute solvent delay. The ionization 
energy was set at 70 eV and the mass range was m/z 40-550. 
 
Liquid chromatography - mass spectrometry 
LC-MS analyses, equipped with an electrospray ionization source, were performed on 
an Agilent 1100 LC system. The column (Allure PFP Propyl, 5 µm, 50 × 2.1 mm) 
was from Restek (Bellefonte, PA, USA) and the aqueous mobile phase A consisted of 
0.05% formic acid in water whereas mobile phase B was prepared from 0.05% formic 
acid in acetonitrile, respectively. The Agilent LC-MSD settings were as follows: 
positive electrospray mode, capillary voltage 3000 V, drying gas (N2) 12 L/min at 
350 °C, nebulizer gas (N2) pressure 60 psi, m/z 50-500, fragmentor voltage either 50 
V or 120 V. Samples for LC-MS analysis (2 µL injection volume) were dissolved in 
acetonitrile/water (1:1, containing 0.1% formic acid) at a concentration of 5 µg/mL. 
The following gradient elution program was used: 0-5 min 12% A and then increased 
to 35% over 30 min using a linear gradient. The flow rate was 1 mL/min and the 
column temperature was 30 °C.  
  
 
Nuclear magnetic resonance spectroscopy 
Page 10 of 29
http://mc.manuscriptcentral.com/dta
Drug Testing and Analysis
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
10 
 
Samples were prepared in DMSO-d6. 1H (600 MHz) and 13C (150 MHz) NMR spectra 
were recorded on a Bruker AV600 NMR spectrometer using a 5 mm TCI cryoprobe. 
1H NMR spectra were referenced to an external TMS reference at δ = 0 ppm. 
 
High-resolution electrospray mass spectrometry 
HR-ESI mass spectra were recorded by direct injection into a LTQ Orbitrap 
Discovery (Thermo Fisher, UK). Samples were dissolved in acetonitrile/water (1:1, 
containing 0.1% formic acid) and infused at a rate of 5 µL/min. Full accurate high-
resolution (30000) mass scans were performed in positive electrospray mode. 
Measured accurate masses were within ± 5ppm of the theoretical masses. The 
following conditions were used: drying gas (N2) 10000 mL/min, capillary temperature 
310  °C, spray voltage 4 V, capillary voltage 22 V and tube lens 77 V. 
X-ray crystallography  
Data for the by-product C14H19BrN2 (colourless needle, 0.060 mm x 0.090 mm 
x 0.220 mm) were collected on a Bruker APEX DUO using Mo Kα radiation (λ = 
0.71073 Å) using a MiTeGen micromount and at 100(2) K (Oxford Cobra 
Cryosystem). Bruker APEX2!software was used to collect and reduce data, determine 
the space group, solve and refine the structure.[19] A total of 2942 frames were 
collected. The total exposure time was 12.26 hours. Absorption corrections were 
applied using SADABS 2012.[20] All final refinements were performed with SHELXL 
2014/3.[21] All non-hydrogen atoms were refined anisotropically. Hydrogen atoms 
were assigned to calculated positions using a riding model. 
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Crystal Data: C14H19BrN2, M = 295.22, Monoclinic, a = 11.2256(3), b = 7.4874(2), c 
= 16.0597(5) Å, β = 99.3230(10)°, U = 1332.00(7) Å3, T = 100 K, space group P21/c, 
Z = 4, µ (Mo Kα) = 3.067 mm−1, ρ = 1.472 Mg/cm3, 86862 reflections collected, 4895 
independent (Rint = 0.0263), aR1 = 0.0205, wR2 = 0.0517 (I > 2σ(I)), S = 1.045.  
aR1 = Σ||Fo| − |Fc||/Σ|Fo|, wR2 = [Σw(Fo2 − Fc2)2/Σw(Fo2)2]1/2.   
(CCDC 1033669 contains the supplementary crystallographic data for this paper. 
These data can be obtained free of charge from The Cambridge Crystallographic Data 
Centre via www.ccdc.cam.ac.uk/data_request/cif.) 
 
 
Results and discussion 
The analytical characterization of synthetic cathinones is a relatively recent research 
field. Typically, the unique determination of substances in most forensic and law 
enforcement laboratories rely on various separation technologies linked to mass 
spectrometric detection. In the analysis of submitted samples where cathinone 
structures are suspected, particular attention is paid to the base peak that is generally 
formed from whatever side chain substitution pattern is present in the cathinone. The 
molecular ion for substituted cathinones in EI mass spectrometry (70 eV) may not be 
easily identifiable; hence molecular weights may not easily be ascertained. Typical 
cathinone fragmentation patterns are dominated by alpha-cleavage and formation of 
immonium ions. In cases where charge retention is observed following alternative 
alpha cleavage, substituted benzoyl ions are then detected.[22] Although analytical data 
on mephedrone are abundantly available, published information on synthetic routes, 
possible by-products or possible route specific compounds are not available.  
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The present investigation reports on the identification and characterization of 1,2,3,5-
tetramethyl-4-(4-methylphenyl)-1H-imidazol-3-ium salt (TMMPI) obtained as a by-
product during the synthesis of mephedrone. As previously stated, when diethyl ether 
was added to synthesised crude mephedrone product (in preparation of forming a 
mephedrone salt), a solid product precipitated out of solution that was filtered, dried 
and stored at -20 °C for further work. Initially, GC-MS analysis was performed on 
this product and the chromatogram obtained which surprisingly showed two distinct 
peaks at 15.58 min and 17.54 min, respectively (see supplemental 1a). The GC 
retention time and mass spectra associated with these two peaks were not consistent 
with the retention time or mass spectra of the expected synthesis product mephedrone. 
The GC-MS spectra of the synthesis by-product were similar to each other each 
having a base peak at m/z 200 but some differences were also noted. The 
fragmentation obtained for the compound at 17.54 min showed the second largest 
peak at m/z 185 following the loss of a methyl group from the base peak at m/z 200. 
This m/z 185 was much less abundant in the compound eluting at 15.58 min. 
Interestingly, a relatively large m/z 132 present in the species at 15.58 min was 
observed (suggesting loss of a neutral C4H6N moiety from the base peak) but this was 
not detected in the chromatographic peak at 17.54 min. A potential explanation is  
that the formation of the m/z 132 ion would require the breakage of two double bonds 
in the imidazolium structure proposed for the by-product, which is energetically less 
favoured compared to only one double bond breakage that could account for the m/z 
132 ion formation associated with the compound eluting first. Two interconverting 
structures could give rise to the mass spectra obtained via loss of either C4H6N or 
C5H9N and subsequent rearrangement of the imidazole ring (see supplemental 1b). 
An LC-MS analysis was performed on the mephedrone synthesis product and the 
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chromatogram consisted of a single peak, which supported the suggestion that the 
presence of two GC chromatographic peaks were formed artificially under GC-MS 
conditions. The electrospray ionization mass spectrum (180 V) showed a base peak at 
m/z 215  (C14H19N2+) and the second most abundant product ions was observed at m/z 
132, presumably due to the loss of C5H9N from the base peak and even-electron 
molecular mass (Figure 1a). Ions observed at m/z 200, m/z 199 and m/z 185 might 
have reflected the loss of CH3, CH4 and C2H6, respectively. The imidazolium ring 
may also undergo opening with the loss of C3H5N or C3H6N to yield m/z 160 and m/z 
159, and further losses from m/z 159 (H or CH3) gave m/z 158 and m/z 144 
respectively. A suggested mechanism is provided in Figure 1b. The difference 
between the GC-MS base peak and the LC-MS base peak also indicated possible 
thermal degradation during GC-MS analysis (loss of a methyl moiety) since ions 
above the m/z 200 base peak in the GC-MS spectrum were not detected.  
 
The solid state crystal structure of the mephedrone by-product was also obtained.  The 
structure of the mephedrone by-product was found to be a bromide salt and shown to 
consist of a para-methyl substituted phenyl ring attached to a tetra-methyl substituted 
five-membered heterocyclic imidazole ring (Figure 2). The bromine atom was only 
weakly coordinated to the organic moiety via CH…Br interactions (3.75 - 3.98Å) and 
each Br- linked four organic moieties together. The twist between the rings (torsion 
angle N7-C9-C10-C16, 133.6(1) Å) allowed the alternating packing of the 
imidazolium/phenyl system into a stack parallel to the b-axis (supplemental 2). This 
arrangement allowed the rings to overlap and align with an intermolecular centroid 
(C13-C15-C16-C10-C11-C12) to centroid (N3-C5-N7-C9-C2) distance of ca. 3.6Å. 
The characterization of the mephedrone by-product added to the few structurally 
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known tetramethylimidazolium-R+ X- compounds (R = Me, X = I; R = CH2I, X = I; R 
= Me, X = (SCN)4Crphenanthroline; R = Me, X = (SCN)4Cr(NH3)2; R = Me, X = 
N(SO2CF3)2). [22-27]  
 
A mechanism of formation is proposed to account for the formation of TMMPI during 
mephedrone synthesis (Figure 3). The carbonyl group on mephedrone was thought to 
undergo a reduction to the alcohol followed by dimerization and subsequent loss of 
water. This intermediate in which the carbonyl functional group is directly attached to 
the 4-methylphenyl moiety was proposed to undergo losses of 4-methylbenzaldehyde 
and a hydride ion to yield the imidazolium by-product.  
Confirmation of the mechanisms proposed by-products was obtained when a series of 
micro scale experiments were performed using cathinone substituents in which the 
alpha-alkyl group was either H, CH3, CH2CH3 and CH2CH2CH3. The corresponding 
substituted by-products were observed when the reaction solvent was methanol, 
ethanol, acetonitrile and tetrahydrofuran. It is significant and noteworthy that in the 
absence of air during these micro experiments, a considerable reduction > 90% was 
observed in the formation of TMMPI by-product. This reduction may be due to the 
absence of an efficient mechanism to regenerate the hydride ion in the proposed 
mechanism in the absence of air and hence a corresponding reduction in by-product 
formation. The regeneration of the hydride ion may have some analogous mechanism 
to those found in biological processes. For example, dihydrobenzo-imidazoles have 
been the subject of extensive studies for hydride transfer mechanisms which might 
make the phenyl-1H-imidazol-3-ium by-products observed in this study useful as 
potential organic hydride donors.[28] 
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The results of the micro scale experiments are presented in Figure 4A-D where the 
TMMPI product was shifted in mass based on the nature of the alpha-alkyl group (R) 
during LC-MS analysis, i.e. at m/z values of 187, 215, 243 and 271, respectively. 
When R was an ethyl-substituted cathinone, a peak was observed in the expected LC 
window of the R as a methyl substituted cathinone at m/z 215. Co-injection into the 
LC-MS of the CH3 and CH2CH3 micro experiments, clearly show that the second 
peak observed in the m/z 215 target window is an artifact and not the mephedrone by-
product (see figure 4 B, C. co-injected). 
Additional confirmation for the unambiguous identification of the mephedrone by- 
product as TMMPI was obtained from its organic synthesis via the reaction of 4-
methyl-1-phenyl-2-bromo-propan-1-one with acetamidine and potassium carbonate 
(Figure 5). The synthesized compound and the mephedrone by-product was then 
compared using GC-MS, LC-MS and NMR and found to be identical (supplemental 
data 3, NMR data). 
 
Analysis of the reaction products derived from in-house synthesis of mephedrone 
showed that the imidazolium by-product was observed in the crude reaction mixture 
along with mephedrone and a mephedrone dimer. GC-MS data clearly showed the 
presence of two peaks at the expected retention times (supplemental data 4a). LC-MS 
data also showed the presence of a single peak at the corresponding retention time 
expected for TMMPI in addition to the expected ESI mass spectrum (supplemental 
data 4b). 
 
Mephedrone freebase was placed in acetonitrile and allowed stand for 48 hours, 
which resulted in the formation of both an oil and a solid. Mephedrone was not 
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detected in both forms but analysis of these reaction products indicated that along 
with the formation of TMMPI an additional compound was detected. Proton NMR of 
the solid indicated the presence of extra peaks in addition to those expected for 
TMMPI, thus suggesting that a para substituted aromatic compound with a methyl 
substituent was also present in the solid (supplemental data 5a).  
 LC-MS (negative electrospray ionization) analysis of both the oil and solid indicated 
that this additional compound had a deprotonated [M-H]- m/z 135  (supplemental data 
5b). GC-MS analysis of both forms provided indication that it was consistent with 4-
methyl benzoic acid (supplemental data 5c). The scheme outlining the formation of 
the TMMPI (Figure 3) showed the loss of 4-methylbenzaldehyde from an 
intermediate and its subsequent oxidation could have been consistent with the 
formation of 4-methyl benzoic acid or it could have been formed by another oxidative 
pathway. 
 
In the investigation of sites where the manufacture of mephedrone (or other 
substituted cathinones) is suspected, it is important that identification of substances 
that can be related to a synthesis route are fully explored. The analytical data 
presented here will be beneficial to such investigations, as any imidazolium by-
product found will give an indication as to what substituted cathinone was 
synthesized. The imidazolium salts will most likely be found amongst the waste 
products at a clandestine lab site. It is often the case, that waste products are either 
dumped in remote locations or are the only items remaining at such illicit synthesis 
sites when enforcement personnel actually get to examine a premises suspected of 
having been used in illicit clandestine manufacture. This may be the case were 
significant by-products are identifiable and associated with a particular class of 
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cathinones. The typical forensic analytical approach taken when examining items 
seized at a suspected clandestine laboratory facility or of suspected waste material 
generated at such a manufacturing site and dumped at a different location is to 
initially screen such samples by GC-MS. If this is the sole screening methodology, 
then challenges may be encountered when attempting to identify the imidazolium 
salts due to GC-induced isomerization and thermal degradation. It is vital that 
analytical strategies utilized for clandestine laboratory investigations are fit for 
purpose and investigators should be aware that some traditional screening 
technologies may have unforeseen limitations. 
 
 
Conclusion 
 
The majority of forensic examinations of drug submissions involve samples with 
questionable origin. Verifiable data for samples derived from clandestine 
manufacturing conditions remain illusive unless such operations are found while in 
production and with products being available. The ability to determine a potential link 
to clandestine production with the identification of a by-product linkable to a known 
synthesis route would be a very valuable forensic option.  This study explored the 
relationship between a synthetic route commonly used for mephedrone production 
and the formation of a specific imidazolium by-product identified as a 1,2,3,5-
tetramethyl-4-(4-methylphenyl)-1H-imidazol-3-ium salt. Furthermore, it was also 
established that mephedrone freebase was unstable in several organic solvents. Given 
the polar nature of the imidazolium salt formed during a mephedrone synthesis, it is 
conceivable that it might be found amongst the waste products generated at such 
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clandestine manufacturing sites or it may be formed post synthesis and as in our 
initial belief presumed to be mephedrone. The present study was aimed to support 
clandestine forensic investigations by targeting specific compounds and the analytical 
strategies which are applicable to the analysis of waste products that are generally 
either dumped or remain abandoned at sites after production has ceased. 
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Figure 1a:                 LC-MS chromatogram of imidazolium by-product. 
Figure 1b:                  LC-MS proposed fragmentation of imidazolium by-product. 
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Supplemental data 
 
1A  GC-MS of imidazolium by-product. 
1B Two interconverting structures for TMMPI in GC inj port 
2 X-Ray crystallography supplemental 2.  
2. Packing diagram of the mephedrone by-product viewed 
down the b-axis. (A) hydrogen atoms shown with dashed lines 
indicating weak CH…Br interactions.(B) Hydrogen atoms 
removed for clarity to show the alternating head-to-tail packing 
assembly of the organic moiety. 
 
 
3 TMPPI synthesized and the mephedrone by-product NMR 
4  Crude mephedrone mixture analysis by GC-MS (4a), LC-
MS (4b) 
5 Mephedrone freebase mixture analysis by NMR (5a), LC-
MS (5b) and GC-MS (5c) 
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